Angiex, Inc.

Beth Israel Deaconess Medical Center, Inc.

Shou-Ching S Jaminet

Harold F Dvorak

Paul A Jaminet

Leonard G Presta

Edward H Ha

Manish S Hudlikar

Conjugates are provided, comprising a targeting protein, e.g., an anti-TM4SFI antibody or antigen or binding fragments thereof. Methods of manufacture and use of said conjugates are also described.

Antibody-oligonucleotide conjugates

Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.

Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same

Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.

Anti-TM4SF1 antibodies and methods of using same

This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.

Growing community of inventors

Cambridge, MA, United States of America

Shou-Ching S Jaminet